Breast surgery for low-grade ductal carcinoma may not improve survival
the ONA take:
According to a new study published in JAMA Surgery, researchers from Brigham and Women's Hospital in Boston, Massachusetts, have found that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) experienced no difference in survival compared with those who did not receive surgery.
For the retrospective analysis, researchers analyzed data from over 50,000 cases of DCIS available from the Surveillance, Epidemiology and End Results (SEER) database between 1998 and 2011. All patients were treated at Dana-Farber/Brigham and Women's Cancer Center.
Results showed that patients with low-grade DCIS who did not receive surgery at or shortly after diagnosis had a 10-year survival rate of 98.8% compared with 98.6% for those who did receive surgery; however, women with intermediate- or high-grade DCIS, the survival rate was significantly higher for those who had surgery versus those who did not.
The researchers note that a prospective clinical trial is warranted before it can be concluded that breast surgery should be avoided for women with low-grade DCIS.
Breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ experienced no difference in survival.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|